The Harvard Global Health Catalyst Win-Win Initiative (cited here as The Win-Win initiative) aims at the increase of affordability better value cancer care in the underserved regions in the world via scientific approaches and win-win scenarios that consider the interests of different stakeholders. The gap is widening between the required clinical oncology services and what is available. Hence, it is not productive to continue to enumerate barriers and obstacles without exploring classic and innovative approaches to lessen their burden. Lack of financial resources-particularly in sub-Saharan Africa is frequently cited as one of the main problems. Africa is not of limited resources but we believe that it has resources that are not well mobilized to serve the cause of increase of clinical oncology cancer care. For all the underserved regions in the world this mobilisation needs an effective campaign and advocating (e.g the Win-Win Ambassadors), new strategies, stimulation of realistic incentives of stakeholders. For education and directed training The Win-Win launched The Global Oncology University (The GO-U) as a world online university with training in different sites. We also established ecancer4all (ecancer4all.com) and a consortium for researches focused on serving the cause of The Win-Win Initiative ( www.icedoc.org/winwin.htm)

Childhood cancer treatment is often assumed to be expensive and out of the reach of low- and middle-income countries (LMICs), particularly in the Sub-Saharan African region. This assumption prevents childhood cancer from being prioritized by LMIC health policymakers and Ministries of Health. Emerging and recent evidence indicates that contrary to the above assumption, childhood cancer treatment units may represent very cost-effective interventions in Sub-Saharan Africa. In this presentation, this evidence will be reviewed. Case studies of how these data are being used to influence policy change will also be discussed. Finally, future directions in health economics research pertaining to childhood cancer will be reviewed, and with the audiences help, priorities for future studies identified.